We are reporting from the 2020 ASCO Virtual Scientic Program!
We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Dr Melissa Johnson on some of the practice-changing lung cancer data being presented, Dr Milind Javle on some pivotal gastrointestinal cancer abstracts, and Dr Hope Rugo on the biggest studies in breast cancer.
Welcome to OncLive News Network! I’m Gina Columbus.
An analysis of data collected in the COVID-19 and Cancer Consortium registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 compared with patients in remission or with no evidence of disease.
Additional updates from the global TERAVOLT Consortium registry showed that chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.
In the phase 3 BOSTON trial, initial results showed that the triplet of selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and objective response rate compared with twice weekly bortezomib/dexmaethasone. Rates of peripheral neuropathy were significantly reduced with numerically fewer deaths on the selinexor arm versus the doublet.
In an interim analysis of the phase 3 KEYNOTE-177 trial, pembrolizumab doubled progression-free survival versus chemotherapy in patients with newly diagnosed microsatellite instability—high/mismatch repair deficient metastatic colorectal cancer.
At a median follow-up of 32.4 months, the median PFS was 16.5 months with pembrolizumab versus 8.2 months with standard chemotherapy with or without bevacizumab or cetuximab in patients with MSI-H/dMMR mCRC, leading to a 40% reduction in the risk of disease progression or death.
Adding avelumab to best supportive care improved median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma in the phase 3 JAVELIN Bladder 100 study. The results showed that the addition of the PD-L1 inhibitor reduced the risk of death by 31%.
In lung cancer, adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non—small cell lung cancer, in an interim analysis of the phase 3 ADAURA trial.
Additionally, in patients with stage IB to IIIA disease, which was the overall study population, osimertinib demonstrated a 79% reduction in the risk of disease recurrence or death.
In patients with relapsed/refractory classical Hodgkin lymphoma, pembrolizumab was superior to brentuximab vedotin and demonstrated statistically significant and clinically meaningful improvement in progression-free survival across all subgroups in the phase III KEYNOTE-204 trial. The data suggest that the PD-1 inhibitor should be the standard of care for this patient population.
In the phase 2 TROPHIMMUN trial, gestational trophoblastic tumors that resist chemotherapy can be treated with frontline avelumab, making the PD-L1 inhibitor the first immunotherapy to show efficacy in treating patients with GTT.
In the INFORM registry, results showed the feasibility of implementing a large-scale multinational personalized oncology platform to aid in decision-making and improve clinical benefit. INFORM also provided diagnostic refinement and targeted therapy options to pediatric patients.
That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location at the 2020 ASCO Virtual Scientific Program, when we sit down with Dr. Roy Herbst with his take on the most significant studies in lung cancer, as well as Dr. Brian Rini, and Dr. Christopher Sweeney, on the biggest news happening in genitourinaery cancers.
Thank you for watching OncLive News Network! I’m Gina Columbus.